Article Text

PDF
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-α blocking agents
  1. E H Halvorsen1,
  2. E A Haavardsholm2,
  3. S Pollmann1,
  4. A Boonen3,
  5. D van der Heijde2,4,
  6. T K Kvien2,
  7. Ø Molberg1,5
  1. 1
    Institute of Immunology, Faculty of Medicine, University of Oslo and Rikshospitalet University Hospital, Oslo, Norway
  2. 2
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  3. 3
    Department of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
  4. 4
    Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  5. 5
    Department of Rheumatology, Rikshospitalet University Hospital, Oslo, Norway
  1. Eirik Hornes Halvorsen, Institute of Immunology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway; eirikhha{at}rr-research.no

Abstract

Background: Peptidylarginine deiminase 4 (PAD4) may generate epitopes targeted by anticitrullinated protein antibodies in rheumatoid arthritis (RA). A subset of patients with RA has serum autoantibodies to human recombinant PAD4 (hPAD4). Here, we assessed whether anti-hPAD4 status in RA predicted disease outcome after antitumour necrosis factor (anti-TNF)-α therapy.

Methods: We analysed RA sera obtained at baseline (n = 40) and after 1 year on anti-TNF-α therapy (n = 33) for anti-hPAD4 IgG. Association analyses between baseline anti-hPAD status and disease progression were performed.

Results: We found that 17 of 40 patients (42.5%) were serum anti-hPAD4 positive at baseline, and the anti-hPAD4 IgG levels were stable over 1 year on anti-TNF-α therapy. At baseline, there were indications that anti-hPAD4 positive patients had more severe disease than the negative patients. After 1 year on anti-TNF-α therapy, the anti-hPAD4 positive patients displayed a persistently elevated disease activity score using 28 joint counts score and increased progression in the van der Heijde–modified Sharp erosion score. Accordingly, more anti-hPAD4 positive than negative patients presented an increase in van der Heijde–modified Sharp erosion scores >0 over 1 year.

Conclusions: Anti-hPAD4 IgG can be detected in a subset of RA sera and the levels are stable after initiation of anti-TNF-α therapy. Serum anti-hPAD4 may predict persistent disease activity and radiographic progression in patients with RA receiving anti-TNF-α therapy.

Statistics from Altmetric.com

Footnotes

  • Competing interests: Hans Bijlsma was the Handling Editor for this article.

  • Funding: This work was supported by grants from Rikshospitalet University Hospital and the Research Council of Norway. EHH is financed by a PhD stipend from the University of Oslo.

  • ▸ Additional supplemental tables 1 and 2 are published online only at http://ard.bmj.com/content/vol68/issue2

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.